Skip to main content
Top
Published in: International Journal of Hematology 6/2011

01-06-2011 | Images in Hematology

Rebound enlargement of an ectopic cervical thymus mimicking relapse of lymphoblastic lymphoma

Authors: Tadashi Matsubayashi, Shin-ichi Shimizu, Hironobu Kitazawa, Rie Matsubayashi, Shigeo Tobayama

Published in: International Journal of Hematology | Issue 6/2011

Login to get access

Excerpt

A previously healthy 6-year-old boy was referred to our hospital with a tumor in the right upper mediastinum on chest X-ray. Physical examination showed no abnormal respiratory sounds, hepatosplenomegaly, or palpable tumor. On MRI, a right mediastinal tumor, 37 × 38 × 25 mm in size, with low intensity on T1-weighted images and high intensity on T2-weighted images was seen. A left-sided cervical mass, 27 × 29 × 10 mm in size, and several small lesions were seen in the liver and kidneys; all were of intensities similar to those of the mediastinal tumor (Fig. 1a, b). On histopathological examination of the biopsied samples from the mediastinal tumor, diffuse proliferation of medium-sized atypical lymphocytes with scant cytoplasm and fine chromatin was seen (Fig. 2); immunohistochemistry was positive for CD79a, CD10, and CD34, and negative for CD3, CD7, and CD20. Bone marrow aspiration showed a normocellular marrow with 5.4% lymphoblasts, suggesting involvement of lymphoma cells. These findings led to a diagnosis of precursor B-cell lymphoblastic lymphoma (LBL) stage IV.
Metadata
Title
Rebound enlargement of an ectopic cervical thymus mimicking relapse of lymphoblastic lymphoma
Authors
Tadashi Matsubayashi
Shin-ichi Shimizu
Hironobu Kitazawa
Rie Matsubayashi
Shigeo Tobayama
Publication date
01-06-2011
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0879-7

Other articles of this Issue 6/2011

International Journal of Hematology 6/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine